ORTEXORTEX News
Live short interest, options flow, and signals — free on ORTEX.Sign up free →
Market Commentary

Now I have enough signals from the screening data to write the article. Let me focus on the standout options-relevant data points: the semiconductor sweep showing massive positive options bets (MU, AM

By ORTEX News · Edited by , Editor, ORTEX NewsUpdated 1 min read

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit

Now I have enough signals from the screening data to write the article. Let me focus on the standout options-relevant data points: the semiconductor sweep showing massive positive options bets (MU, AMD, INTC), Centene's top options score with an RSI of 86, and Cytokinetics' elevated short score combined with options interest ahead of a pending catalyst.

Semis Sweep the Options Board

Semiconductor names dominated bullish options flow this week. Micron Technology topped the positive bets leaderboard. The stock is up 179% year-to-date with RSI at 79. Options traders loaded up on calls, betting the run has further to go.

SanDisk Corporation followed close behind. It has gained a staggering 512% in 2026. Options expiries stretch out to August, suggesting traders are positioning for a sustained move, not a quick flip.

Advanced Micro Devices and Intel Corporation also drew heavy bullish contract flow. Intel is up 251% year-to-date. The last active options expiry cluster sits in July. That window aligns with anticipated chipmaker earnings catalysts.

Sentiment shifted on Centene Corporation. The managed-care stock scored the highest options score in the US market this week. RSI hit 86 — deep overbought territory. Traders may be using near-term calls to chase a breakout, or puts as a hedge against a pullback.

Cytokinetics drew attention in biotech options. Its short score stands at 58. Options expiries are sparse — just five dates through August — pointing to concentrated positioning ahead of clinical catalysts.

QXO carries 22 days to cover and an options score showing bullish skew. That combination of heavy short interest and call buying raises squeeze potential.

How this article was generated

Generated
13 May 2026, 20:44
Prompt version
migrated
Data sources
Options flowORTEX Alpha signalsAlt DataIndex Rebalance

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.